Glaxosmithkline Share News (GSK)

UK MORNING BRIEFING: Direct Line Leads Rising Market On Cash Return

Glaxo Names Royal Bank Of Scotland's Philip Hampton As Next Chairman

GSK chooses Philip Hampton as next chairman

LONDON, Sept 25 (Reuters) - GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman. He will join the board in January and will become chairman with effect from Sept. 1, 2015, or at an earlier date if released from oth

Thursday newspaper round-up: RBS, GSK, Barclays, BP

Sir Philip Hampton, the chairman of Royal Bank of Scotland (RBS) is to quit his role at in charge of the bank and take on the same role at pharmaceutical company GlaxoSmithKline (GSK), The Guardian reported on Thursday. Confirming rumours reported here on Wednesday, Hampton will succeed Sir Christop

PRESS: Glaxo Poised To Appoint RBS' Hampton As Chairman - FT

Adaptimmune raises $104 mln to develop immune-system cancer drugs

LONDON, Sept 25 (Reuters) - British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells. The Oxford-based private company plans to use the money to advance its programmes to clinical tr

GSK to name Hampton as new chairman this week -Sky News

LONDON, Sept 24 (Reuters) - GlaxoSmithKline will this week name Philip Hampton as its next chairman, Sky News reported on Wednesday. Reuters reported on Monday that Britain's biggest drugmaker was under pressure to make changes, including a possible early replacement of existing chairman Ch

UPDATE 2-Record U.S. tipster payout a warning for big business abroad

(Recasts, adds China detail) By Sarah N. Lynch and Adam Jourdan WASHINGTON/SHANGHAI, Sept 23 (Reuters) - U.S. regulators will pay a record $30 million bounty to an anonymous whistleblower outside the United States, underlining the growing reach of the country's watchdogs and creating

BUZZ-GlaxoSmithKline Plc: Goldman Sachs upgrades to "buy"

** Drugmaker's shares up 0.33 pct at $47.52 in heavy premarket trade ** Analysts from Goldman Sachs upgraded their rating on the company's stock to "buy" from "neutral", citing safe dividends, sustainable franchises and optionality on more structural change as key reasons ** "On a sl

After China, GlaxoSmithKline faces pressure for change

* Investors unhappy after bribery scandal, poor U.S. sales * New drugs fail to plug gap left by Advair's decline * Some investors demand new chairman, CEO faces criticism * GSK says chairman succession planning "well under way" By Ben Hirschler and Simon Jessop LONDO

Monday broker round-up UPDATE

Avation: WH Ireland shifts target price from 200p to 206p and maintains a buy recommendation BAE Systems: UBS raises target price from 460p to 505p and reiterates a buy recommendation. Centrica: Goldman Sachs ups target price from 385p to 396p leaving its buy recommendation unchanged. Chariot Oil

UK BROKER RATINGS: Goldman Sachs Raises GlaxoSmithKline To Buy

UK MORNING BRIEFING: Tesco Leads London Declines After Another Shock

Sunday newspaper round-up: Lloyds, Marks&Spencer, Oil explorers

Lloyds Banking Group is considering moving its legal home to England from Scotland even after the Scots voted against leaving the UK, the Mail on Sunday reported. Lloyds had said it would move if Scotland voted to leave the union but has only said it would keep "a significant presence" in Scotland a

Sunday share tips: GlaxoSmithKline, African Minerals, WANdisco

Buy shares of GlaxoSmithKline, Questor said in the Sunday Telegraph. China's £297m fine against GSK for corruption is manageable and has lifted the cloud that hung over the company. The shares have underperformed the wider market and are trading on 15.3 times forecast earnings compared with 22 times